



# Dr Allen's Therapeutic Devices Should be Implemented in the Healthcare System for the Treatment of Chronic Noncancerous Prostate and Kidney Diseases Saving People's Well-Being and Money

Simon Allen<sup>1,\*</sup>

<sup>1</sup>Fine Treatment, Oxford, United Kingdom

\*Corresponding author: Director, Fine Treatment, 14 Drew House, Islip, Road Oxford, OX2 7SL, Oxford, United Kingdom. Tel: +44-7958878300, Email: info@finetreatment.com

Received 2018 June 19; Revised 2018 August 15; Accepted 2018 August 18.

## Abstract

**Background:** Innovative thermobalancing therapy (TT) with Dr Allen's therapeutic device (DATD) treats affected organs by the energy of one's own body. 10 years empirical evidence has shown that the use of DATD helps to recover from chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and benign prostatic hyperplasia (BPH), and to dissolve kidney stones. Moreover, the cost of DATD compares favourably with the cost of conventional treatments.

**Objectives:** The purpose of this study is to point to the introduction of TT from DATD to the Primary Health Care system.

**Methods and Results:** Two clinical trials observed dynamics of urinary symptoms by International Prostate Symptom Score (IPSS), quality of life (QoL), ultrasound prostate volume (PV mL) and uroflowmetry (maximum flow rate,  $Q_{max}$  mL/s) in men with BPH and chronic prostatitis. These trials have explored that TT with DATD reduced: prostate volume from 45 mL to 31 mL ( $P < 0.001$ ) and, consequently, lower urinary tract symptoms, from 14.2 to 4.9 ( $P < 0.001$ ) in the treatment group 124 patients with BPH; and pain score, from 10.38 to 3.58 ( $P < 0.001$ ), and decrease of prostate volume from 31 mL to 27 mL ( $P < 0.001$ ) in the treatment group of 45 men with CP/CPPS. The QoL improved in both treatment groups significantly. In the control groups: in 124 men with BPH in watchful waiting, and in 45 men with chronic prostatitis on standard treatment, no significant difference in parameters was observed. 10 years empirical evidence showed that DATD treats both kidneys simultaneously, dissolving kidney stones, despite their size and type.

**Conclusions:** The outcomes of clinical studies and empirical evidence demonstrated the high effectiveness of TT, which was prescribed as mono-therapy. This therapy is side effects free. It is easy to use Dr Allen's device, which is a class 1 medical device that doesn't require involvement of a notified body. Therefore, TT with DATD should be implemented in the primary health care system as a self-managing treatment for chronic diseases.

**Keywords:** Chronic Diseases, Chronic Pain, Thermobalancing Therapy, Enlarged Prostate, Kidney Stones, Healthcare, Chronic Prostatitis

## 1. Background

### 1.1. Prevalence

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is the most common disease of the prostate gland in men under 50 that reduce their quality of life. However, the optimal treatment for chronic prostatitis is not possible yet due to the unknown etiology of the diseases (1, 2).

Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) most often encountered in men over the age of 50 and the mild symptoms can be found in 75.3% of men (3). The prevalence of BPH in Iran is less, about 36% in those > 70years (4).

The incidence in kidney stone disease rises in the last decade worldwide with rates ranging from 7 to 13% in North America, 5% - 9% in Europe, and 1% - 5% in Asia (5). The prevalence of kidney stones in Iran is 5.7%. The average cumulative recurrence rate was 16% after 1 year, 32% after 5 years, and 53% after 10 years, which is very important in terms of recommended treatment options for these people (6).

### 1.2. Standard Treatment Options

Pharmacological interventions and alternative management strategies for CP/CPPS are subject of serious analysis as none of treatment option is effective (7).

Medical and surgical treatments available for BPH have sexual side effects that can negatively affect a patient's quality of life that is important for physicians to discuss with their patients before initiating treatment. Alpha blockers relax the bladder muscles, making it easier to urinate but cause tiredness, headaches, dizziness and others. 5 alpha reductase inhibitors, such as Finasteride and Avodart act at the hormonal level easing urination but cause impotence, depression, testicle pain, and even diabetes. (8).

Extracorporeal shock wave lithotripsy (ESWL) for kidney stones have usual side effects such as bleeding, pain, and urinary tract infections, and rare complications spleen rupture or intrarenal hematoma (9, 10). The long-term adverse medical events after ESWL are high blood pressure and diabetes mellitus (11, 12). Surgical procedures on kidneys are not safe.

Though percutaneous nephrolithotomy (PCNL) is a minimal access surgery, yet it may have many devastating and life-threatening complications. Postoperative fevers occur transiently in 30% of patients undergoing PCNL, while sepsis may develop in 3% of cases. Injury to the renal collecting system occurs in 8% of patients. The rate of pleural injury after PCNL reaches 1%; and adjacent solid organs are also at risk of injury. The incidence of residual stones after PCNL ranges from 10% to 60% (13, 14).

### 1.3. Debates About Other Treatments.

Many people with CP/CPPS, BPH and kidney stone disease are not satisfied with conventional treatment options and they try alternative therapies: diet and lifestyle modifications, phytotherapy, acupuncture, myofascial physical therapy, and psychosocial factors (15-17). The symptoms CP/CPPS can worsen from spicy food, coffee, alcoholic beverages, while other nutrients, such as psyllium, water, herbal teas, and polycarbophil, can improve condition of patients with this disorder (18). The use of diet is now considered between the important factors affecting prostate health, particularly in the aging male with BPH (19). The similar view that nephrolithiasis is associated with metabolic syndrome is widely discussed (20). However, none of these methods showed proven effectiveness.

### 1.4. What is Suggested Here?

Although BPH, kidney stone disease and chronic prostatitis have troubling symptoms, they are non-life-threatening conditions. Therefore, these chronic internal diseases should be treated therapeutically in the first place.

Thermobalancing therapy (TT) with Dr Allen's therapeutic device (DATD) were developed for the treatment of

chronic internal diseases naturally by the long-term application of a source of energy that does not exceed the normal body temperature (21). This therapy has demonstrated pain relief and improvement of quality of life (QoL) in men with CP/CPPS (22, 23). TT with DATD diminishes LUTS due to BPH, by reducing the enlarged prostate volume (24, 25). The use of DATD in people with kidney stones for over 10 years established its ability to dissolve kidney stones (26).

### 1.5. Etiology and Pathophysiology

TT is based on a new understanding of The origin of diseases. The etiology and pathophysiology of CP/CPPS, BPH and kidney stones can be explained by changes in small blood vessels in the affected tissues, namely the pathological activity of capillaries. In response to initial triggers-such as inflammation, cold, stress and other factors, the constriction of capillaries follows (27) that creates the focus of hypothermia, the secondary irritating trigger, that leads to spontaneous expansion of a capillary net (28). Slowly expanded capillaries form an extra tissue creating pressure in the organ, which leads to its malfunction. This pressure inside the tissue is also responsible for the continuous compression of small vessels, which makes the problem chronic (29).

## 2. Objectives

This article is intended to show that TT with DATD is able to terminate the pathological activity of capillaries, enhancing blood circulation in the affected organs, i.e. in a prostate gland and kidneys. And to demonstrate the importance of the use of TT with DATD in the medical practice in the Primary Health Care system to improve people's lives.

## 3. Methods

### 3.1. Study Protocol

Dr Allen's Device was registered with the Medicines and Healthcare Products Regulatory Agency in the United Kingdom in 2010, as a class 1 medical device. The class 1 medical device without a measuring function and supplied in non-sterile condition does not require the involvement of a notified body. Thus, it is permitted to use TT with DATD by everyone at home. For ten years DATD was distributed across the world having customers in more than 100 countries. There were not complains about this safe therapy. However, it was decided to conduct clinical trial.

Ethics committee of the Yerevan State Medical University approved the clinical study with TT and DATD. The studies were registered at the World Health Organisation via the German Clinical Trials Register (DRKS).

TT with DATD was used in the clinical controlled study at the Department of Urology of the Yerevan State Medical University.

### 3.2. Study Design

Two clinical trials were completed. One clinical trial in 124 men with BPH who received TT within 6-month period and their clinical parameters before and after therapy were examined. This information was compared with the control group, i.e. data received from 124 men with BPH who were in watchful waiting stage. Second clinical trial in 45 men with CP/CPPS who received TT within 6-month period and their clinical parameters before and after therapy were examined. This information was compared with the control group, i.e. data received from 45 men with CP/CPPS who did not receive TT.

In patient with BPH was measured International Prostate Symptom Score (IPSS) quality of life. In men with CP/CPPS National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score. In both clinical studies, prostate volume (PV mL) was investigated. The parameters were compared between groups accordingly.

### 3.3. Participants

For about 3-year period, 45 males (age < 55 years) with CP/CPPS (NIH category III) and 124 men with LUTS due to BPH, from a total of 226 men were selected for clinical trial with PV < 60 mL were received treatment with Dr Allen's Device at the clinical trials at the Department of Urology of the Yerevan State Medical University. In the control groups: in 124 men with BPH in watchful waiting, and in 45 men with chronic prostatitis on standard treatment. Patients were selected in conjunction with urologists.

### 3.4. Evaluation

Baseline evaluations were a full physical examination, medical history, digital rectal examination, serum biochemistry, measurement of prostate-specific antigen and electrolytes, urinalysis, and renal function tests. Evaluations were made at baseline and 6 months after treatment. Dynamics of the symptoms and indicators in each group were assessed at the beginning and end of treatment using NIH-CPSI and IPSS. Ultrasound was used to determine the volume of the prostate gland (PV mL).

Evaluation at baseline shows that characteristics of men were identical between treatment and control groups in the CP/CPPS and BPH studies.

### 3.5. Statistical Analyses

The independent-samples *t*-test and paired-samples *t*-test are suitable only for interval and ratio data, so the Wilcoxon signed-rank test was employed.  $P < 0.05$  was considered significant. Statistical analyses were carried out using SPSS v22 (IBM, Armonk, NY, USA).

### 3.6. DATD

DATD applies a special mixture of waxes (thermoelement) topically to the projection of affected organ. In men with prostate problems to the coccyx area. In people with kidney stones disease to the projection of kidneys in the back (Figure 1). The thermoelement accumulates the emitted body heat, and turns into a source of energy itself. DATD applies thermoelement tightly to the skin tightly, thereby overcoming the skin barrier and spreading the energy towards the prostate gland or kidneys. It is comfortable to wear these devices.

## 4. Results

### 4.1. Prostate Volume (PV) mL and Pain Score in Men with CP/CPPS

There was a significant decrease of PV (mL) from  $31.75 \pm 7.0$  to  $27.07 \pm 4.5$  mL ( $P < 0.001$ ) and pain score from  $10.38 \pm 2.53$  to  $3.58 \pm 2.54$  ( $P < 0.001$ ) in the treatment group. In the control group changes were insignificant. These results suggested that TT decreases PV and pain in men with CP/CPPS (Figure 2).

### 4.2. Prostate Volume and Urinary Symptoms Score in Men with BPH

In the treatment group prostate volume decreased from  $45.1 \pm 3.9$  mL to  $31.8 \pm 4.1$  mL ( $P < 0.001$ ) and urinary symptoms score decreased from  $14.3 \pm 3.3$  to  $4.9 \pm 2.7$  ( $P < 0.001$ ). In the control group changes were insignificant or even worse. These results suggest that DATD reduces PV and UrS significantly (Figure 3).

### 4.3. Side Effects of Thermobalancing Therapy with DATD

Side effects of thermobalancing therapy with DATD were not observed.


## 5. Discussion

### 5.1. Main Findings

The use of TT with DATD: reduces volume of the inflamed prostate and pain score in patients with CP/CPPS dramatically, whereas in the control group changes were insignificant. In men with BPH the size of enlarged



**Figure 1.** DATD tightly attaches thermoelement(s) to the coccyx area in a man for prostate treatment and to the back of a woman in the projection of kidneys to dissolve kidney stones.




**Figure 2.** Dynamics of prostate volume (PV mL) by ultrasound and pain score in 45 men with CP/CPPS and in the control group measured by the National Institute of Health-Chronic Prostatitis Symptom Index (NIH-CPSI).

prostate has been reduced expressively and, consequently, LUTS relief have been achieved. At the same time, the prostate size in men with BPH in watchful waiting increased and urinary symptoms worsened. QoL in men with CP/CPPS and BPH after using therapeutic device improved significantly. Of course, this improvement in QoL is dependent on the decrease in the size of the inflamed prostate in

men CP/CPPS and the reduction in the size of the enlarged prostate in men with BPH after thermobalancing therapy.

10 years empirical evidence have shown the unique opportunity of thermobalancing therapy help people to dissolve kidney stones. Patients with kidney stone disease have dissolved kidney stones without renal colic, side effects and complications. This study presents observations



**Figure 3.** Prostate volume (PV mL) by ultrasound and Urinary symptoms (UrS) measured by the International Prostate Symptom Score (IPSS) in 124 men with BPH after 6-month Thermobalancing therapy and in the control group.

of four patients who have suffered from kidney stone disease for a certain period of time, from 5 months to 30 years. All of them dissolved stones in the kidneys, since they did not have any renal colic after using DATD.

These facts can be explained from the point of view that long-term application of the source of energy to the prostate gland and kidneys treats the underlying cause of these chronic diseases. DADT reduces the size of inflamed or enlarged prostate gland by enhancing blood circulation in the organ that improves its functioning and, consequently pain and urinary symptoms. The same with kidneys. It should be noted that none of patients with kidney stone disease has complained that the device does not help. The presented data confirm that TT should be valued as an effective independent treatment for these chronic conditions.

5.2. Economic

The importance of this study based on the high incidence rate of CP/CPPS, BPH and kidney stones and the high costs of their treatments. For instance, the annual per person costs of treatment of a man with CP/CPPS in 2007 were estimated as \$6534 (30).

The investigation in Europe of annual cost of BPH medical treatment was lowest in the UK about \$1000 and highest in Poland approximately \$1500 (31).

The annual cost of kidney stone disease in 2000 was approximately \$2.81 billion, and with increase of population

in 2014 it raised to \$3.79 billion, and it is estimated the increase the cost of stone disease by \$780 million in 2030 (32).

The use of TT with DATD, with the price for a unit less than \$200, would make significant changes in the costs of these common urological diseases.

5.3. Pathogenesis of Chronic Disease Due to Changes at the Vascular Level

Outcomes of the study of TT with DATD in men with CP/CPPS confirm the view that the vascular factor plays the major role in the pathophysiology of this disease (33). It has also been determined that chronic pain, which is a manifesting symptom of CP/CPPS, is a consequence of the problem at the capillary level, namely, the micro-focus of hypothermia, which in turn causes an expansion of the capillary network, and this additional tissue increases the pressure on nociceptors causing pain (34).

In recent years, researchers have suggested that the pathogenesis of BPH may be associated with vascular dysfunction, prostatic hypoxia, pelvic ischemia and elevated pressure in the prostate gland (35-37). The use of DADT by keeping the source of energy, accumulated from the body, in the projection of the prostate gland for a prolonged period, have deactivated micro-focus of hypothermia and spontaneous expansion of capillaries, thereby relieving the pressure in the prostate tissue and reducing the enlarged prostate in size (38, 39). The ability of TT with DATD to dissolve kidney stones can be explained by

**Box 1.** Presents Empirical Data from Patients with Kidney Stone Disease<sup>a, b</sup>**The Empirical Evidence in Patients with Kidney Stone Disease before and after Wearing DATD for Prolonged Period****Patient A: (Male, 69 years old)**

Kidney stones in both kidneys, large in left.

Renal colic often from 1995.

Used DATD periodically from 2000.

Renal calculi were dissolved, no renal colic after 2002.

**Patient B: (Female, 44 years old)**

Kidney stones history for 20 years.

Had renal colic every year.

Used DATD from January to May 2016.

After 2 weeks pain and other symptoms are gone, until now.

**Patient C: (Male, 58 years old)**

Kidney stones history for 30 years.

3cm renal stone, lithotripsies in history, CKD.

Used DATD from March to December 2014.

3cm stone was dissolved, kidneys function improved.

**Patient D: (Male, 41 years old)**

Was diagnosed with kidney stone Nov 2009.

Several renal colic within 5 months.

Used DATD from March to December 2010.

Some twinges first 2 - 3 months but no recurrences since.

<sup>a</sup> People suffered from this disease for many years and dissolved kidney stones using TT with DATD.<sup>b</sup> The data in this box demonstrates that DATD is effective for kidney stone disease in men and women as renal colic were not registered after its use.

increased blood circulation in the kidneys. This sheds light on the pathophysiology of the formation of kidney stones due to changes in them at the vascular level.

#### 5.4. Conclusions

TT with DATD can be used as mono-therapy for CP/CPPS, BPH and kidney stones, as they improve patient's condition without adverse side effects and complications.

DATD treats the cause of chronic diseases by using own human body energy, through innovative TT.

TT with DATD is an economical solution for chronic disease management, as the price is cost-effective compared to various treatment options.

People have a key role in protecting their own health, choosing appropriate treatments and managing long-term conditions.

TT with DATD should be implemented into the medical practice.

TT with DATD can improve people's lives.

TT with DATD can significantly reduce pressure on the healthcare system.

TT with DATD should be offered to patients and administered by primary healthcare services.

#### Acknowledgments

I am grateful to the staff of the Department of Urology at the Yerevan State Medical University and the Mikaelyan Institute of Surgery, Yerevan, Armenia, for their help in supervision of patients during the studies.

#### Footnote

**Funding/Support:** These studies were not supported by Grant

#### References

1. Abdollahi A, Etemadian M, Shoar S, Nozarian Z. Is helicobacter pylori infection a risk factor for prostatitis? a case-control study in a referring tertiary care center. *Iran J Pathol.* 2016;**11**(4):323.
2. Chung SD, Huang CC, Lin HC. Chronic prostatitis and depressive disorder: a three year population-based study. *J Affect Disord.* 2011;**134**(1-3):404-9. doi: 10.1016/j.jad.2011.05.046. [PubMed: 21665291].

3. Rohrmann S, Katzke V, Kaaks R. Prevalence and Progression of Lower Urinary Tract Symptoms in an Aging Population. *Urology*. 2016;**95**:158–63. doi: [10.1016/j.urology.2016.06.021](https://doi.org/10.1016/j.urology.2016.06.021). [PubMed: [27346671](https://pubmed.ncbi.nlm.nih.gov/27346671/)].
4. Safarinejad MR. Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older. *Int Urol Nephrol*. 2008;**40**(4):921–31. doi: [10.1007/s11255-008-9338-7](https://doi.org/10.1007/s11255-008-9338-7). [PubMed: [18246438](https://pubmed.ncbi.nlm.nih.gov/18246438/)].
5. Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y. Epidemiology of stone disease across the world. *World J Urol*. 2017;**35**(9):1301–20. doi: [10.1007/s00345-017-2008-6](https://doi.org/10.1007/s00345-017-2008-6). [PubMed: [28213860](https://pubmed.ncbi.nlm.nih.gov/28213860/)].
6. Safarinejad MR. Adult urolithiasis in a population-based study in Iran: prevalence, incidence, and associated risk factors. *Urol Res*. 2007;**35**(2):73–82. doi: [10.1007/s00240-007-0084-6](https://doi.org/10.1007/s00240-007-0084-6). [PubMed: [17361397](https://pubmed.ncbi.nlm.nih.gov/17361397/)].
7. Franco JV, Turk T, Jung JH, Xiao YT, Iakhno S, Garrote V, Vietto V. Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. *Cochrane Database Syst Rev*. 2018;**12**(5). doi: [10.1002/14651858.CD012551.pub3](https://doi.org/10.1002/14651858.CD012551.pub3). [PubMed: [29757454](https://pubmed.ncbi.nlm.nih.gov/29757454/)].
8. Voznesensky I, Shaw E, DeLay KJ, Yafi F, Hellstrom WJG. Benign prostatic hyperplasia treatment options and their effects on sexual function. *Sex Med Rev*. 2017;**5**(1):87–102. doi: [10.1016/j.sxmr.2016.05.006](https://doi.org/10.1016/j.sxmr.2016.05.006).
9. Marinkovic SP, Marinkovic CM, Xie D. Spleen injury following left extracorporeal shockwave lithotripsy (ESWL). *BMC Urol*. 2015;**15**:4. doi: [10.1186/1471-2490-15-4](https://doi.org/10.1186/1471-2490-15-4). [PubMed: [25972225](https://pubmed.ncbi.nlm.nih.gov/25972225/)]. [PubMed Central: [PMC4429660](https://pubmed.ncbi.nlm.nih.gov/PMC4429660/)].
10. Akbulut F, Kucuktopcu O, Ucpinar B, Savun M, Ozgor F, Sonmezay E, et al. A rare complication of extracorporeal shock wave lithotripsy: Intrarenal hematoma mimicking pelvis renalis tumor. *Case Rep Urol*. 2015;**2015**:1–4. doi: [10.1155/2015/719618](https://doi.org/10.1155/2015/719618).
11. Krambeck AE, Gettman MT, Rohlinger AL, Lohse CM, Patterson DE, Segura JW. Diabetes mellitus and hypertension associated with shock wave lithotripsy of renal and proximal ureteral stones at 19 years of followup. *J Urol*. 2006;**175**(5):1742–7. doi: [10.1016/j.s0022-5347\(05\)00989-4](https://doi.org/10.1016/j.s0022-5347(05)00989-4).
12. D'Addressi A, Vittori M, Racioppi M, Pinto F, Sacco E, Bassi P. Complications of extracorporeal shock wave lithotripsy for urinary stones: to know and to manage them a review. *ScientificWorldJournal*. 2012;**2012**:619820. doi: [10.1100/2012/619820](https://doi.org/10.1100/2012/619820). [PubMed: [22489195](https://pubmed.ncbi.nlm.nih.gov/22489195/)]. [PubMed Central: [PMC3317539](https://pubmed.ncbi.nlm.nih.gov/PMC3317539/)].
13. Said SHA, Al Kadum Hassan MA, Ali RHG, Aghaways I, Kakamad FH, Mohammad KQ. Percutaneous nephrolithotomy; alarming variables for postoperative bleeding. *Arab J Urol*. 2017;**15**(1):24–9. doi: [10.1016/j.aju.2016.12.001](https://doi.org/10.1016/j.aju.2016.12.001).
14. Malik I, Wadhwa R. Percutaneous nephrolithotomy: Current clinical opinions and anesthesiologists perspective. *Anesthesiol Res Pract*. 2016;**2016**:1–7. doi: [10.1155/2016/9036872](https://doi.org/10.1155/2016/9036872).
15. Herati AS, Moldwin RM. Alternative therapies in the management of chronic prostatitis/chronic pelvic pain syndrome. *World J Urol*. 2013;**31**(4):761–6. doi: [10.1007/s00345-013-1097-0](https://doi.org/10.1007/s00345-013-1097-0). [PubMed: [23740129](https://pubmed.ncbi.nlm.nih.gov/23740129/)].
16. Lukacs B, Cornu JN, Aout M, Tessier N, Hodee C, Haab F, et al. Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in France: a comprehensive population study. *Eur Urol*. 2013;**64**(3):493–501. doi: [10.1016/j.eururo.2013.02.026](https://doi.org/10.1016/j.eururo.2013.02.026). [PubMed: [23465519](https://pubmed.ncbi.nlm.nih.gov/23465519/)].
17. Moyad MA. Lifestyle changes, CAM, and kidney stones: heart health = kidney health. *Complementary and alternative medicine for prostate and urologic health*. New York: Springer Science and Business Media; 2014. p. 201–29. doi: [10.1007/978-1-4614-8492-9\\_8](https://doi.org/10.1007/978-1-4614-8492-9_8).
18. Herati AS, Shorter B, Srinivasan AK, Tai J, Seideman C, Lesser M, et al. Effects of foods and beverages on the symptoms of chronic prostatitis/chronic pelvic pain syndrome. *Urology*. 2013;**82**(6):1376–80. doi: [10.1016/j.urology.2013.07.015](https://doi.org/10.1016/j.urology.2013.07.015). [PubMed: [23978369](https://pubmed.ncbi.nlm.nih.gov/23978369/)].
19. Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. *Int J Endocrinol*. 2014;**2014**. doi: [10.1155/2014/329456](https://doi.org/10.1155/2014/329456). [PubMed: [24688539](https://pubmed.ncbi.nlm.nih.gov/24688539/)]. [PubMed Central: [PMC3943333](https://pubmed.ncbi.nlm.nih.gov/PMC3943333/)].
20. Rendina D, De Filippo G, D'Elia L, Strazzullo P. Metabolic syndrome and nephrolithiasis: a systematic review and meta-analysis of the scientific evidence. *J Nephrol*. 2014;**27**(4):371–6. doi: [10.1007/s40620-014-0085-9](https://doi.org/10.1007/s40620-014-0085-9). [PubMed: [24696310](https://pubmed.ncbi.nlm.nih.gov/24696310/)].
21. Allen S, Adjani A. *Therapeutic device and method, United States Patent and Trademark Office*. 2016. Available from: <https://www.google.com/patents/US9408744>.
22. Allen S, Aghajanyan IG. Effect of thermobalancing therapy on chronic prostatitis and chronic pelvic pain syndrome. *J Clin Urol*. 2016;**10**(4):347–54. doi: [10.1177/2051415816671036](https://doi.org/10.1177/2051415816671036).
23. Aghajanyan I, Allen S. Positive response to thermobalancing therapy enabled by therapeutic device in men with non-malignant prostate diseases: BPH and chronic prostatitis. *Diseases*. 2016;**4**(4):18. doi: [10.3390/diseases4020018](https://doi.org/10.3390/diseases4020018).
24. Allen S, Aghajanyan IG. Benign prostatic hyperplasia treatment with new physiotherapeutic device. *Urol j*. 2015;**12**(5):2371–6. [PubMed: [26571324](https://pubmed.ncbi.nlm.nih.gov/26571324/)].
25. Allen S, Aghajanyan IG, Schumacher U. Thermobalancing conservative treatment for moderate-to-low-degree lower urinary tract symptoms (LUTS) secondary to prostate enlargement. *Cogent Med*. 2016;**3**(1). doi: [10.1080/2331205x.2016.1195067](https://doi.org/10.1080/2331205x.2016.1195067).
26. Allen S. Thermobalancing therapy@ should be the first-line treatment for kidney stones and benign prostatic hyperplasia, discussions at the medical conferences. *ARC J Urol*. 2017;**2**(3):1–8. doi: [10.20431/2456-060x.0203001](https://doi.org/10.20431/2456-060x.0203001).
27. Baldwin AL. Introduction: a brief history of capillaries and some examples of their apparently strange behaviour. *Clin Exp Pharmacol Physiol*. 2000;**27**(10):821–5. [PubMed: [11022976](https://pubmed.ncbi.nlm.nih.gov/11022976/)].
28. Hansen-Smith FM. Capillary network patterning during angiogenesis. *Clin Exp Pharmacol Physiol*. 2000;**27**(10):830–5. [PubMed: [11022978](https://pubmed.ncbi.nlm.nih.gov/11022978/)].
29. Allen S. The origin of chronic diseases can be in capillary pathology: an evidence from clinical trials on thermobalancing treatment of prostate reveals. *Ach Life Sci*. 2016;**10**(2):197–202. doi: [10.1016/j.als.2016.11.005](https://doi.org/10.1016/j.als.2016.11.005).
30. Clemens JQ, Markossian T, Calhoun EA. Comparison of economic impact of chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis/painful bladder syndrome. *Urology*. 2009;**73**(4):743–6. doi: [10.1016/j.urology.2008.11.007](https://doi.org/10.1016/j.urology.2008.11.007).
31. Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. *BJU Int*. 2015;**115**(4):508–19. doi: [10.1111/bju.12745](https://doi.org/10.1111/bju.12745).
32. Antonelli JA, Maalouf NM, Pearle MS, Lotan Y. Use of the national health and nutrition examination survey to calculate the impact of obesity and diabetes on cost and prevalence of urolithiasis in 2030. *Europ Urol*. 2014;**66**(4):724–9. doi: [10.1016/j.eururo.2014.06.036](https://doi.org/10.1016/j.eururo.2014.06.036).
33. Allen S, Aghajanyan IG. New independent thermobalancing treatment with therapeutic device for chronic prostatitis/chronic pelvic pain syndrome. *Nephrourol Mon*. 2017;**9**(2). doi: [10.5812/nu-monthly.44694](https://doi.org/10.5812/nu-monthly.44694).
34. Allen S. The vascular factor plays the main role in the cause of pain in men with chronic prostatitis and chronic pelvic pain syndrome: the results of clinical trial on thermobalancing therapy. *Diseases*. 2017;**5**(4):25. doi: [10.3390/diseases5040025](https://doi.org/10.3390/diseases5040025).
35. Saito M, Tsounapi P, Oikawa R, Shimizu S, Honda M, Sejima T, et al. Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH. *Sci Rep*. 2014;**4**(1). doi: [10.1038/srep03822](https://doi.org/10.1038/srep03822).
36. Thurmond P, Yang JH, Azadzoi KM. LUTS in pelvic ischemia: a new concept in voiding dysfunction. *Am J Physiol Renal Physiol*. 2016;**310**(8):F738–43. doi: [10.1152/ajprenal.00333.2015](https://doi.org/10.1152/ajprenal.00333.2015). [PubMed: [26792064](https://pubmed.ncbi.nlm.nih.gov/26792064/)].
37. Cohen PG. Abdominal obesity and intra-abdominal pressure: a new

- paradigm for the pathogenesis of the hypogonadal-obesity-BPH-LUTS connection. *Horm Molecul Biol Clin Invest*. 2012;**11**(1):317-20.
38. Allen S. Innovative thermobalancing therapy can help millions of men with enlarged prostate gland to improve the quality of life and well-being throughout the world. *World Sci News*. 2018;**105**:51-61.
39. Allen S, Aghajanyan I. Use of thermobalancing therapy in ageing male with benign prostatic hyperplasia with a focus on etiology and pathophysiology. *Aging Male*. 2017;**20**(1):28-32. doi: [10.1080/13685538.2016.1247151](https://doi.org/10.1080/13685538.2016.1247151). [PubMed: [27960590](https://pubmed.ncbi.nlm.nih.gov/27960590/)].